SpringWorks Therapeutics, Inc. (SWTX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
24.65+3.88 (+18.68%)
At close: 04:00PM EST
23.70 -0.95 (-3.85%)
After hours: 04:18PM EST

SpringWorks Therapeutics, Inc.

100 Washington Boulevard
Stamford, CT 06902
United States
203 883 9490

Full-time employees227

Key executives

NameTitlePayExercisedYear born
Mr. Saqib Islam J.D.CEO & Director1.26MN/A1970
Mr. Francis I. Perier Jr., M.B.A.Chief Financial Officer710.6kN/A1960
Dr. Badreddin Edris Ph.D.Chief Operating Officer998.61kN/A1987
Dr. L. Mary Smith PH.D.Chief Development Officer817.17kN/A1967
Mr. Bhavesh AsharChief Commercial Officer729.62kN/A1966
Mr. Michael P. NofiChief Accounting OfficerN/AN/A1971
Mr. Tai-An Lin Ph.D.Chief Scientific OfficerN/AN/AN/A
Ms. Kim DiamondVice President of Communications & Investor RelationsN/AN/AN/A
Mr. Herschel S. Weinstein J.D.General Counsel & Secretary568.64kN/A1956
Mr. Daniel J. PichlChief People Officer428.51kN/A1983
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

Corporate governance

SpringWorks Therapeutics, Inc.’s ISS governance QualityScore as of 28 November 2023 is 8. The pillar scores are Audit: 7; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.